ALLYSON GRIMALDI: Open Payments
NPI 1912422106 · PITTSBURG, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$637 in 39 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $478 · 2025 $637
Food & beverage: $637
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $151 |
| Astellas Pharma US Inc | 3 | $76 |
| AstraZeneca Pharmaceuticals LP | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| Novo Nordisk Inc | 2 | $38 |
| Lundbeck LLC | 1 | $31 |
| Amgen Inc. | 2 | $30 |
| Exact Sciences Corporation | 2 | $28 |
| Abbott Laboratories | 1 | $25 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
Products named: REXULTI, Veozah, UBRELVY, VRAYLAR, FARXIGA, Cologuard Collection Kit, FREESTYLE LIBRE 3, Wegovy.
Industry payments across KS — which companies pay providers there.
